002864

21.701.72%

BOJI CRO's subsidiary plans to transfer the technology of "Glucosamine Sulfate Capsules" to Panlong Pharmaceutical

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, BOJI CRO (300404.SZ) announced that the company, its wholly-owned subsidiary Guangzhou Huasheng Pharmaceutical Co., Ltd. (referred to as "Huasheng Pharmaceutical"), and Panlong Pharmaceutical jointly signed a "Technology Transfer Contract." After friendly consultations among the three parties, Huasheng Pharmaceutical will transfer the technology of "Glucosamine Sulfate Capsules" to Panlong Pharmaceutical, with a total transfer fee of 4.5 million yuan. If this transaction is successfully implemented, it will have a positive impact on the company's operating performance

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.